לברסט

Land: Israel

Språk: hebraisk

Kilde: Ministry of Health

Aktiv ingrediens:

LETROZOLE 2.5 MG

Tilgjengelig fra:

RAFA LABORATORIES LTD

ATC-kode:

L02BG04

Legemiddelform:

FILM COATED TABLETS

Administreringsrute:

PER OS

Produsert av:

SIEGFRIED GENERICS ( MALTA) LTD

Terapeutisk gruppe:

LETROZOLE

Indikasjoner:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Autorisasjon dato:

2012-04-01